Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions:: A meta-analysis of randomized, controlled trials

被引:27
作者
Araújo, JODF
Veloso, HH
De Paiva, JMB
Wafae, M
De Paola, AAV
机构
[1] Hosp Venerovel Ordem Terceira Penitencia VOTCOR, BR-20530001 Rio De Janeiro, Brazil
[2] Univ Fed Sao Paulo, Escola Paulista Med, Dept Cardiol, Sao Paulo, Brazil
关键词
D O I
10.1016/j.ahj/2004.05.047
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To evaluate the efficacy and safety of abciximab following acute myocardial infarction (AMI) treated with, percutaneous coronary interventions. Methods A meta-analysis of randomized controlled trials of platelet glycoprotein IIb/IIIa inhibitor abciximab as adjunctive therapy to percutaneous coronary interventions for AMI was performed. Main outcomes measured were: (i) mortality, (2) reinfarction, (3) target vessel revascularization (TVR), (4) major cardiac events (MACE) that were a composite endpoint of death, reinfarction, and TVR, and (5) major bleeding. Results Six trials randomized 3755 patients who were followed for a mean of 5.5 months. Compared with the control, abciximab significantly reduced mortality (OR 0.70, 95% Cl 0.50-0.97), TVR (0.79, 95% CI 0.65-0.96) and MACE (0.76, 95% Cl 0.65-0.90). Reduction on TVR and MACE was confirmed in stent patients, bug not in balloon angioplasty patients. Abciximab was associated with an increased risk of major bleeding (OR 1.39, 95% CI 1.03-1.87), but bleeding was observed only with a 100U/kg heparin bolus followed by a maintenance infusion (OR 1.89, 95% Cl 1.10-3.28) and not with a bolus of 70U/kg (OR 1.22, 95% Cl 0.85-1.73). Conclusions Abciximab, as adjunctive therapy to percutaneous coronary interventions, reduces mortality, TVR and MACE following AMI. The reduction of clinical outcomes occurs with stent implantation but not with balloon angioplasty 70U/kg heparin bolus must be used to avoid major bleeding.
引用
收藏
页码:937 / 943
页数:7
相关论文
共 25 条
  • [1] A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction
    Antoniucci, D
    Rodriguez, A
    Hempel, A
    Valenti, R
    Migliorini, A
    Vigo, F
    Parodi, G
    Fernandez-Pereira, C
    Moschi, G
    Bartorelli, A
    Santoro, GM
    Bolognese, L
    Colombo, A
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (11) : 1879 - 1885
  • [2] Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation
    Antoniucci, D
    Valenti, R
    Migliorini, A
    Moschi, G
    Trapani, M
    Dovellini, EV
    Bolognese, L
    Santoro, GM
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (04) : 353 - 357
  • [3] Mortality and reinfarction reduction with primary stent implantation compared with primary balloon angioplasty
    Araújo, JOQF
    Veloso, HH
    Paiva, JMB
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (09) : 1043 - 1044
  • [4] Abciximab in primary coronary angioplasty for acute myocardial infarction improves short- and medium-term outcomes
    Azar, RR
    McKay, RG
    Thompson, PD
    Hirst, JA
    Mitchell, JF
    Fram, DB
    Waters, DD
    Kiernan, FJ
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (07) : 1996 - 2002
  • [5] Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
    Brener, SJ
    Barr, LA
    Burchenal, JEB
    Katz, S
    George, BS
    Jones, AA
    Cohen, ED
    Gainey, PC
    White, HJ
    Cheek, HB
    Moses, JW
    Moliterno, DJ
    Effron, MB
    Topol, EJ
    [J]. CIRCULATION, 1998, 98 (08) : 734 - 741
  • [6] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY
    CALIFF, RM
    SHADOFF, N
    VALETT, N
    BATES, E
    GALEANA, A
    KNOPF, W
    SHAFTEL, J
    BENDER, MJ
    AVERSANO, T
    RAQUENO, J
    GURBEL, P
    COWFER, J
    COHEN, M
    CROSS, P
    BITTL, J
    EDDINGS, K
    TAYLOR, M
    DEROSA, K
    HATTEL, L
    COOPER, L
    ESHELMAN, B
    FINTEL, D
    NIEMYSKI, P
    KLEIN, L
    KENNEDY, H
    THORNTON, T
    KEREIAKES, D
    MARTIN, L
    ANDERSON, L
    HIGBY, N
    ELLIS, S
    BREZINA, K
    GEORGE, B
    CHAPEKIS, A
    SMITH, D
    ANWAR, A
    GERBER, TL
    PRITCHARD, GL
    MYLER, R
    SHAW, R
    MURPHY, M
    WARD, K
    MADIGAN, NP
    BLANKENSHIP, J
    HALBERT, M
    FLANAGAN, C
    TANNENBAUM, M
    POLICH, M
    STEVENSON, C
    TCHENG, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) : 956 - 961
  • [7] Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction
    Chan, AW
    Chew, DP
    Bhatt, DL
    Moliterno, DJ
    Topol, EJ
    Ellis, SG
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (02) : 132 - 136
  • [8] Glycoprotein IIb/IIIa inhibition in the setting of acute ST-segment elevation myocardial infarction
    Eisenberg, MJ
    Jamal, S
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (01) : 1 - 6
  • [9] Relation of stenting to decreased coronary blood flow during primary angioplasty in acute myocardial infarction
    Escobar, J
    Guarda, E
    Marchant, E
    Fajuri, A
    Martínez, A
    Pichard, A
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (12) : 1410 - +
  • [10] Rescue angioplasty in the thrombolysis in myocardial infarction (TIMI) 4 trial
    Gibson, CM
    Cannon, CP
    Greene, RM
    Sequeira, RF
    Margorien, RD
    Leya, F
    Diver, DJ
    Baim, DS
    Braunwald, E
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (01) : 21 - 26